Fluoroquinolone Antimicrobial Agents in the Treatment of Prostatitis and Recurrent Urinary Tract Infections in Men

Overview

Journal Curr Infect Dis Rep

Specialty Infectious Diseases

Date 2004 Dec 22

PMID 15610666

Citations 8

Authors

F M E Wagenlehner

K G Naber

Affiliations

Soon will be listed here.

Abstract

Chronic bacterial prostatitis is the most frequent cause for recurrent urinary tract infection in young and middle-aged men. The selection of an appropriate antimicrobial agent that has optimal pharmacokinetics for urine and prostatic secretion and tissue is important in both entities. Fluoroquinolones possess several pharmacologic characteristics that favor them for treatment of urinary tract infection and prostatitis. The pharmacokinetics of fluoroquinolones and the theoretical background of drug penetration into the prostate are outlined. Analyzing the concentrations of various fluoroquinolones in urine, prostatic and seminal fluid, and in prostatic tissue, it becomes obvious that the fluoroquinolones differ in plasma concentrations and in their concentrations at these sites. Nevertheless, overall, the concentrations at the site of infection of most of the fluoroquinolones should be sufficient for the treatment of chronic bacterial prostatitis and vesiculitis and recurrent urinary tract infection in men caused by susceptible pathogens.

Citing Articles

Calculated parenteral initial treatment of bacterial infections: Infections of the kidneys and the genito-urinary tract.

Funfstuck R, Hoyme U, Naber K, Pilatz A, Schubert S, Wagenlehner F GMS Infect Dis. 2020; 8:Doc12.

PMID: 32373437 PMC: 7186803. DOI: 10.3205/id000056.

Population pharmacokinetic modeling of the unbound levofloxacin concentrations in rat plasma and prostate tissue measured by microdialysis.

Hurtado F, Weber B, Derendorf H, Hochhaus G, Dalla Costa T Antimicrob Agents Chemother. 2013; 58(2):678-86.

PMID: 24217697 PMC: 3910848. DOI: 10.1128/AAC.01884-13.

Green tea as an effective antimicrobial for urinary tract infections caused by Escherichia coli.

Reygaert W, Jusufi I Front Microbiol. 2013; 4:162.

PMID: 23785367 PMC: 3684790. DOI: 10.3389/fmicb.2013.00162.

Antibiotic resistance pattern among common bacterial uropathogens with a special reference to ciprofloxacin resistant Escherichia coli.

Mandal J, Acharya N, Buddhapriya D, Parija S Indian J Med Res. 2013; 136(5):842-9.

PMID: 23287133 PMC: 3573607.

Treatment duration of febrile urinary tract infections.

van der Starre W, van Dissel J, Van Nieuwkoop C Curr Infect Dis Rep. 2011; 13(6):571-8.

PMID: 21882085 PMC: 3207126. DOI: 10.1007/s11908-011-0211-y.

References

Mayersak J . Transrectal ultrasonography directed intraprostatic injection of gentamycin-xylocaine in the management of the benign painful prostate syndrome. A report of a 5 year clinical study of 75 patients. Int Surg. 1999; 83(4):347-9. View

Ulleryd P, Zackrisson B, Aus G, Bergdahl S, Hugosson J, Sandberg T . Prostatic involvement in men with febrile urinary tract infection as measured by serum prostate-specific antigen and transrectal ultrasonography. BJU Int. 1999; 84(4):470-4. DOI: 10.1046/j.1464-410x.1999.00164.x. View

Hoepelman A, van Buren M, van den Broek J, Borleffs J . Bacteriuria in men infected with HIV-1 is related to their immune status (CD4+ cell count). AIDS. 1992; 6(2):179-84. DOI: 10.1097/00002030-199202000-00006. View

Smith J, Jones S, REED W, Tice A, DEUPREE R, Kaijser B . Recurrent urinary tract infections in men. Characteristics and response to therapy. Ann Intern Med. 1979; 91(4):544-8. DOI: 10.7326/0003-4819-91-4-544. View

Naber K . Lomefloxacin versus ciprofloxacin in the treatment of chronic bacterial prostatitis. Int J Antimicrob Agents. 2002; 20(1):18-27. DOI: 10.1016/s0924-8579(02)00067-5. View

Lipsky B . Urinary tract infections in men. Epidemiology, pathophysiology, diagnosis, and treatment. Ann Intern Med. 1989; 110(2):138-50. DOI: 10.7326/0003-4819-110-2-138. View

Naber K, Kinzig M, Sorgel F, Weigel D . Penetration of ofloxacin into prostatic fluid, ejaculate and seminal fluid. Infection. 1993; 21(2):98-100. DOI: 10.1007/BF01710740. View

de la Rosette J, Hubregtse M, Meuleman E, Debruyne F . Diagnosis and treatment of 409 patients with prostatitis syndromes. Urology. 1993; 41(4):301-7. DOI: 10.1016/0090-4295(93)90584-w. View

Jimenez-Cruz J, Tormo F, Gomez J . Treatment of chronic prostatitis: intraprostatic antibiotic injections under echography control. J Urol. 1988; 139(5):967-70. DOI: 10.1016/s0022-5347(17)42733-9. View

10.

Naber K, Giamarellou H . Proposed study design in prostatitis. Infection. 1994; 22 Suppl 1:S59-60. DOI: 10.1007/BF01716050. View

11.

Krieger J, Berger R, Ross S, Rothman I, Muller C . Seminal fluid findings in men with nonbacterial prostatitis and prostatodynia. J Androl. 1996; 17(3):310-8. View

12.

Ulleryd P, Sandberg T . Ciprofloxacin for 2 or 4 weeks in the treatment of febrile urinary tract infection in men: a randomized trial with a 1 year follow-up. Scand J Infect Dis. 2003; 35(1):34-9. DOI: 10.1080/0036554021000026988. View

13.

Litwin M, McNaughton-Collins M, Fowler Jr F, Nickel J, Calhoun E, Pontari M . The National Institutes of Health chronic prostatitis symptom index: development and validation of a new outcome measure. Chronic Prostatitis Collaborative Research Network. J Urol. 1999; 162(2):369-75. DOI: 10.1016/s0022-5347(05)68562-x. View

14.

Biering-Sorensen F, Hoiby N, Nordenbo A, Ravnborg M, Bruun B, Rahm V . Ciprofloxacin as prophylaxis for urinary tract infection: prospective, randomized, cross-over, placebo controlled study in patients with spinal cord lesion. J Urol. 1994; 151(1):105-8. DOI: 10.1016/s0022-5347(17)34882-6. View

15.

van der Wall E, Verkooyen R, Mintjes-de Groot J, Oostinga J, van Dijk A, Hustinx W . Prophylactic ciprofloxacin for catheter-associated urinary-tract infection. Lancet. 1992; 339(8799):946-51. DOI: 10.1016/0140-6736(92)91529-h. View

16.

BARNES R, Daifuku R, Roddy R, Stamm W . Urinary-tract infection in sexually active homosexual men. Lancet. 1986; 1(8474):171-3. DOI: 10.1016/s0140-6736(86)90650-1. View

17.

Pust R, Ackenheil-Koppe H, Gilbert P, Weidner W . Clinical efficacy of ofloxacin (tarivid) in patients with chronic bacterial prostatitis: preliminary results. J Chemother. 1989; 1(4 Suppl):869-71. View

18.

Bjerklund Johansen T, Gruneberg R, Guibert J, Hofstetter A, Lobel B, Naber K . The role of antibiotics in the treatment of chronic prostatitis: a consensus statement. Eur Urol. 1998; 34(6):457-66. DOI: 10.1159/000019784. View

19.

Blacklock N, Beavis J . The response of prostatic fluid pH in inflammation. Br J Urol. 1974; 46(5):537-42. DOI: 10.1111/j.1464-410x.1974.tb03853.x. View

20.

Weidner W, SCHIEFER H, Krauss H, Jantos C, Friedrich H, Altmannsberger M . Chronic prostatitis: a thorough search for etiologically involved microorganisms in 1,461 patients. Infection. 1991; 19 Suppl 3:S119-25. DOI: 10.1007/BF01643680. View